Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | GFER | P55789 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.55 |
| ▸ | NPC1 | O15118 | 6/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAOA | P21397 | 3/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | STAT1 | P42224 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | TYR | P14679 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11385164 | 0.85 | MEN1 (0.70) | MEN1KMT2AMAPTSMN1; SMN2GFER | |
| SCHEMBL24590457 | 0.85 | MAOB (0.57) | MEN1KMT2AMAPTSMN1; SMN2GAA | |
| SCHEMBL24590360 | 0.83 | NPY5R (0.57) | MEN1KMT2AMAPTSMN1; SMN2RAB9A | |
| SCHEMBL24590352 | 0.83 | TYR (0.67) | MEN1KMT2AMAPTSMN1; SMN2GAA | |
| SCHEMBL4082533 | 0.83 | MAPT (0.68) | MEN1KMT2AMAPTSMN1; SMN2GAA | |
| SCHEMBL7998302 | 0.83 | MAPK1 (0.63) | MEN1KMT2AMAPTSMN1; SMN2GAA | |
| SCHEMBL1475441 | 0.82 | CSNK2A1 (0.59) | MEN1KMT2AMAPTSMN1; SMN2GAA | |
| SCHEMBL9537775 | 0.81 | NPC1 (0.52) | MEN1KMT2AMAPTSMN1; SMN2GFER | |
| SCHEMBL1474762 | 0.81 | CSNK2A1 (0.56) | MEN1KMT2AMAPTSMN1; SMN2GAA | |
| SCHEMBL24590324 | 0.81 | PTGS2 (0.67) | MEN1KMT2AMAPTSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416960-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| CN-108699035-B | Novel compounds | 特殊治疗有限公司 | 2021-10-15 | — | — | CN | disclosed |
| US-10640498-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-05 | — | — | US | disclosed |
| US-10640498-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-05 | — | — | US | disclosed |
| US-20190055232-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
| US-20190055232-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
| EP-3416960-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017141036-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED (GB) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017141036-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED (GB) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017114742-A1 | A COLORANT COMPOUND, AND A COLORANT MATERIAL COMPRISING THE SAME | IRIDOS LTD. (KR) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017040564-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-03-09 | — | — | WO | disclosed |
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7893020-B2 | can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide | MPEX PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7879795-B2 | can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide | MPEX PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | REMPEX PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
| CN-1735408-A | Receptor function controlling agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-15 | — | — | CN | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640498-B2 | Compounds | USP30, USP20, UBQLN1 | MEN1 3967/4885KMT2A 2948/4885MAPT 1970/4885 |
| US-20190055232-A1 | NOVEL COMPOUNDS | USP30, USP20, USP28 | MEN1 3942/4885KMT2A 2875/4885MAPT 2091/4885 |
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | ABCB1, ABCB11, SLC47A2 | MEN1 4742/4885KMT2A 2401/4885MAPT 4181/4885 |
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | MEN1 2579/4885KMT2A 4408/4885MAPT 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.